Learn more about the potential and limitations of language models in everyday clinical practice!

5 min readPreparations for Next Moonwalk Simulations Underway (and Underwater) In-person participants (L-R) – Back row: Jason Lytle, Stuart Lee, Eric Bershad, Ashot Sargsyan, Aaron Everson, Philip Wells,...

Objectives Clonal hematopoiesis of indeterminate potential (CHIP), marked by age-related somatic mutations in hematopoietic cells, has been linked to cardiovascular disease. Given its shared risk pr...

VTE RESEARCH OPPORTUNITIES Seeking to join, support, develop or share a research project? Please select one of the following for opportunities which may be ...

Study results show that apixaban (Eliquis; Bristol Myers Squibb and Pfizer) for venous thromboembolism showed a lower risk of recurrent blood clots or death within one year of treatment initiation,…

SARS-CoV-2 (COVID-19) infection and multisystem inflammatory syndrome in children (MIS-C) are risk factors for venous thromboembolism (VTE). Guideline…

There is scarce evidence on the effectiveness and safety of recommended-dose direct acting oral anticoagulants (DOACs) in obese patients with venous t…

Background: Achieving optimal adherence to anticoagulation therapy is a major challenge in the management of venous thromboembolism (VTE). Mobile health (mHealth) technologies may offer a scalable approach to supporting medication adherence and self-management. Objective: This pilot study aimed to assess the #feasibility and preliminary impact of a smart technology–assisted, patient-centered care mHealth app for managing VTE (mVTEA) on short-term anticoagulation adherence among patients with VTE or at moderate-to-high risk of VTE. Methods: Baseline medication adherence and beliefs were assessed using the Chinese versions of the 8-item Morisky Medication Adherence Scale and the Beliefs about Medicines Questionnaire–Specific to characterize baseline status only. The primary outcome was perfect adherence at 1 month, assessed through structured telephone interviews, outpatient visits, and the mVTEA physician-patient communication module. During follow-up, researchers verified current medication regimens, recorded missed doses, assessed therapy continuation, and whenever possible, confirmed adherence through pharmacy refill records or remaining medication packaging. Secondary outcomes included the mVTEA check-in rate and clinical safety events (VTE recurrence, major bleeding per International Society on Thrombosis and Haemostasis criteria, VTE-related hospitalizations, VTE-related rehospitalizations, all-cause mortality). Results: In total, 45 participants completed the study (mean age 60.80, SD 15.20 years; n=16, 36% female). Baseline 8-item Morisky Medication Adherence Scale scores indicated suboptimal adherence (mean 6.24, SD 1.80), with 29% (13/45) classified as good adherence and 71% (32/45) as moderate or poor adherence. The primary contributors to nonadherence were forgetting to take medication. Baseline Beliefs about Medicines Questionnaire–Specific scores showed stronger beliefs in medication necessity than concerns (17.58, SD 2.52 vs 14.56, SD 3.34;

The Translational Research Institute for Space Health (TRISH) at Baylor College of Medicine has released a new solicitation seeking proposals to address...